In a mouse model of nonalcoholic fatty liver disease (NAFLD), HW downregulated Nrf2-mediated miR-136 expression by targeting the maternally expressed 3 long noncoding RNA gene [110], providing a rationale for further clinical trials. The gene discussed is NFE2L2; the disease is metabolic dysfunction-associated steatotic liver disease.